Bottle rockets cause permanent vision loss

Article

Bottle rocket injuries can cause serious ocular injury or permanent loss of vision in children and adolescents

Bottle rocket injuries can cause serious ocular injury or permanent loss of vision in children and adolescents, an investigation from the Archives of Ophthalmology has concluded.

The retrospective review, conducted by Ms Mehnaz Khan et al., Vanderbilt University School of Medicine, Nashville, Tennessee, USA, revealed several ocular injuries including corneal epithelial defect, hyphaema, traumatic iris, iridodialysis, cataract, retinal dialysis and vitreous haemorrhage.

Eleven eyes were used from 8 boys and 2 girls aged 5–17 years. The outcome measures consisted of present ocular injuries, interventions needed, the most recent visual acuity and the latest anatomic findings.

Four eyes underwent lensectomy, 2 eyes required corneal debridement, 1 eye required globe exploration and 1 eye needed retinal laser photocoagulation. Secondary interventions were required for 3 patients. This included 1 pars plana vitrectomy, 1 muscle surgery for sensory strabismus and 1 intraocular lens placement.

It was concluded that bottle rocket injuries resulted in permanent damage to vision commonly due to traumatic maculopathy.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.